Advertisement
Advertisement
ENVB
Enveric Biosciences, Inc. Common Stock
1.95
USDSponsored
-0.02
-1.21%
Apr 07, 16:00 UTC -4
Closed
Pre-Market
2.08
+0.14
+6.92%
ENVB Earnings Reports
Positive Surprise Ratio
ENVB beat 11 of 16 last estimates.
69%
Next Report
Date of Next Report
May 12, 2026
Estimate for Q1 26 (Revenue/ EPS)
--
/--
Implied change from Q4 25 (Revenue/ EPS)
--
/--
Implied change from Q1 25 (Revenue/ EPS)
--
/--
Enveric Biosciences, Inc. Common Stock earnings per share and revenue
On Mar 27, 2026, ENVB reported earnings of -- USD per share (EPS) for Q4 25, -- the estimate of -0.31 USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a --% difference. The market reacted with a +1.08% price change (close before vs. close after earnings).
Looking ahead to Q1 26, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Tvardi Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.65
Actual
-$0.78
Surprise
-18.33%
VolitionRX Limited Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.05
Surprise
-22.35%
Tevogen Bio Holdings Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$2.04
Actual
-$1.45
Surprise
+28.92%
Cadrenal Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.18
Actual
-$1.43
Surprise
-20.34%
Sunshine Biopharma Inc.
Report Date
Apr 03, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.54
Surprise
-96.08%
Palvella Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.92
Actual
-$1.07
Surprise
-15.20%
Pharvaris N.V. Ordinary Shares
Report Date
Apr 02, 2026 For Q4 25
Estimate
-$0.63
Actual
-$0.72
Surprise
-13.69%
Forte Biosciences, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.23
Actual
-$1.39
Surprise
-12.31%
Innate Pharma S.A. ADS
Report Date
Apr 01, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.55
Surprise
-353.80%
OS Therapies Incorporated
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.13
Actual
-$0.50
Surprise
-260.49%
FAQ
What were Enveric Biosciences, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Enveric Biosciences, Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to Enveric Biosciences, Inc. Common Stock's Q4 2025 earnings?
The stock price moved up 1.08%, changed from $1.86 before the earnings release to $1.88 the day after.
When is Enveric Biosciences, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 12, 2026.
What are the forecasts for Enveric Biosciences, Inc. Common Stock's next earnings report?
Based on --
analysts, Enveric Biosciences, Inc. Common Stock is expected to report EPS of -- and revenue of -- for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement